| 2025-04-04 |
6-K |
IMFINZI APPROVED IN EU FOR AEGEAN |
View Document |
| 2025-04-04 |
6-K |
ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER |
View Document |
| 2025-04-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-03-31 |
6-K |
CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL |
View Document |
| 2025-03-31 |
6-K |
IMFINZI APPROVED IN THE US FOR BLADDER CANCER |
View Document |
| 2025-03-21 |
6-K |
AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING |
View Document |
| 2025-03-17 |
6-K |
ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT |
View Document |
| 2025-03-17 |
6-K |
IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC |
View Document |
| 2025-03-17 |
6-K |
ASTRAZENECA TO ACQUIRE ESOBIOTEC |
View Document |
| 2025-03-12 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-03-07 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-03-07 |
6-K |
NOTICE OF AGM |
View Document |
| 2025-03-07 |
6-K |
IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER |
View Document |
| 2025-03-07 |
6-K |
FORM 6-K |
View Document |
| 2025-03-06 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-03-05 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-03-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-03-03 |
6-K |
IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN |
View Document |
| 2025-02-28 |
6-K |
ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER |
View Document |
| 2025-02-26 |
6-K |
CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER |
View Document |
| 2025-02-19 |
6-K |
FILING OF FORM 20-F WITH SEC |
View Document |
| 2025-02-18 |
IRANNOTICE |
IRANNOTICE |
View Document |
| 2025-02-18 |
20-F |
FORM 20-F |
View Document |
| 2025-02-18 |
6-K |
FORM 6-K |
View Document |
| 2025-02-18 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-02-18 |
6-K |
ANNUAL FINANCIAL REPORT |
View Document |
| 2025-02-18 |
6-K |
DIRECTORATE CHANGE |
View Document |
| 2025-02-06 |
6-K |
FINAL RESULTS |
View Document |
| 2025-02-05 |
EFFECT |
|
View Document |
| 2025-02-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-02-03 |
6-K |
IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC |
View Document |
| 2025-01-28 |
6-K |
ENHERTU APPROVED IN US FOR BREAST CANCER POST ET |
View Document |
| 2025-01-24 |
SCHEDULE 13D/A |
|
View Document |
| 2025-01-21 |
F-6 |
|
View Document |
| 2025-01-21 |
6-K |
DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER |
View Document |
| 2025-01-17 |
6-K |
CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL |
View Document |
| 2025-01-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-12-26 |
6-K |
DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU |
View Document |
| 2024-12-23 |
6-K |
TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL |
View Document |
| 2024-12-16 |
6-K |
DIRECTORATE CHANGE |
View Document |
| 2024-12-05 |
6-K |
IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC |
View Document |
| 2024-12-04 |
6-K |
ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL |
View Document |
| 2024-12-02 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2024-12-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-11-25 |
6-K |
TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER |
View Document |
| 2024-11-20 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-18 |
6-K |
TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA |
View Document |
| 2024-11-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-12 |
6-K |
ASTRAZENECA INVESTS $3.5 BILLION IN US |
View Document |
| 2024-11-12 |
6-K |
KOMET PHASE III TRIAL MET PRIMARY ENDPOINT |
View Document |
| 2024-11-12 |
6-K |
9M AND Q3 2024 RESULTS |
View Document |
| 2024-11-12 |
6-K |
DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN |
View Document |
| 2024-11-08 |
6-K |
TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS |
View Document |
| 2024-11-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-10-30 |
6-K |
AZN CHINA PRESIDENT UNDER INVESTIGATION |
View Document |
| 2024-10-28 |
SC 13G |
SC 13G |
View Document |
| 2024-10-21 |
6-K |
FORM 6-K |
View Document |
| 2024-10-11 |
SC 13G |
SC 13G |
View Document |
| 2024-10-07 |
6-K |
ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET |
View Document |
| 2024-10-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-09-26 |
6-K |
TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER |
View Document |
| 2024-09-23 |
6-K |
FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA |
View Document |
| 2024-09-23 |
6-K |
FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 |
View Document |
| 2024-09-20 |
6-K |
FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US |
View Document |
| 2024-09-18 |
6-K |
FASENRA EGPA US FDA APPROVAL |
View Document |
| 2024-09-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-09-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-08-16 |
6-K |
IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER |
View Document |
| 2024-08-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-07-30 |
6-K |
ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING |
View Document |
| 2024-07-29 |
6-K |
CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS |
View Document |
| 2024-07-26 |
6-K |
ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER |
View Document |
| 2024-07-25 |
6-K |
FORM 6K |
View Document |
| 2024-07-15 |
6-K |
ACQUISITION OF AMOLYT PHARMA COMPLETED |
View Document |
| 2024-07-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-07-01 |
6-K |
LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL |
View Document |
| 2024-06-26 |
11-K |
ANNUAL REPORT |
View Document |
| 2024-06-25 |
6-K |
UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL |
View Document |
| 2024-06-25 |
6-K |
IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER |
View Document |
| 2024-06-18 |
6-K |
UPDATE ON CAPITELLO-290 PHASE III TRIAL |
View Document |
| 2024-06-17 |
6-K |
IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER |
View Document |
| 2024-06-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-06-04 |
6-K |
FORM 6-K |
View Document |
| 2024-06-04 |
25-NSE |
|
View Document |
| 2024-06-03 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2024-06-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-06-03 |
6-K |
TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU |
View Document |
| 2024-05-28 |
6-K |
DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER |
View Document |
| 2024-05-21 |
6-K |
ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 |
View Document |
| 2024-05-20 |
6-K |
ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE |
View Document |
| 2024-05-16 |
6-K |
SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT |
View Document |
| 2024-05-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-05-07 |
6-K |
ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT |
View Document |
| 2024-05-02 |
6-K |
CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL |
View Document |
| 2024-05-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-04-29 |
6-K |
TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL |
View Document |
| 2024-04-29 |
6-K |
ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW |
View Document |
| 2024-04-25 |
6-K |
1ST QUARTER RESULTS |
View Document |
